ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade

mAbs

Volumn 6, Issue 2, 2014, Pages 523-532

  Silence, Karen ^a   Dreier, Torsten ^a   Moshir, Mahan ^a   Ulrichts, Peter ^a   Gabriels, Sofie M E ^a   Saunders, Michael ^a   Wajant, Harald ^b   Brouckaert, Peter ^c   Huyghe, Leander ^c   Van Hauwermeiren, Tim ^a   Thibault, Alain ^a   De Haard, Hans J ^a  

^a ArGEN X BVBA   (Belgium)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

ARGX 110; CD70; Immune checkpoint blockade; POTELLIGENT

Indexed keywords

ANTINEOPLASTIC AGENT; ARGX 110; CD27 ANTIGEN; CD70 ANTIGEN; MONOCLONAL ANTIBODY; PALIVIZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL PROLIFERATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG TARGETING; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FUCOSYLATION; HUMAN; HUMAN CELL; IC 50; MACACA FASCICULARIS; MOUSE; NONHUMAN; PHAGOCYTOSIS; REGULATORY T LYMPHOCYTE; SURVIVAL;

ARGX-110; CD70; IMMUNE CHECKPOINT BLOCKADE; POTELLIGENT®;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD27; ANTIGENS, CD70; ANTINEOPLASTIC AGENTS; CAMELIDS, NEW WORLD; CELL CYCLE CHECKPOINTS; CELLS, CULTURED; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 84896513277     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.27398     Document Type: Article

References (30)

1. Tesselaar K, Xiao Y, Arens R, van Schijndel GM, Schuurhuis DH, Mebius RE, Borst J, van Lier RA. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J Immunol 2003; 170:33-40; PMID:12496380
2. Bowman MR, Crimmins MA, Yetz-Aldape J, Kriz R, Kelleher K, Herrmann S. The cloning of CD70 and its identification as the ligand for CD27. J Immunol 1994; 152:1756-61; PMID:8120384
3. Hintzen RQ, Lens SM, Koopman G, Pals ST, Spits H, van Lier RA. CD70 represents the human ligand for CD27. Int Immunol 1994; 6:477-80; PMID:8186199; http://dx.doi.org/10.1093/intimm/6.3.477
4. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005; 17:275-81; PMID:15886117; http://dx.doi.org/10.1016/j.coi.2005.04.004
5. Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 1995; 85:3556-65; PMID:7540066
6. Nilsson A, de Milito A, Mowafi F, Winberg G, Björk O, Wolpert EZ, Chiodi F. Expression of CD27-CD70 on early B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL. Exp Hematol 2005; 33:1500-7; PMID:16338493; http://dx.doi.org/10.1016/j.exphem.2005.10.005
7. Loenen WA, De Vries E, Gravestein LA, Hintzen RQ, Van Lier RA, Borst J. The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis. Eur J Immunol 1992; 22:447-55; PMID:1311261; http://dx.doi.org/10.1002/eji.1830220224
8. Kok M, Bonfrer JM, Korse CM, de Jong D, Kersten MJ. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma. Tumour Biol 2003; 24:53-60; PMID:12743427; http://dx.doi.org/10.1159/000070661
9. De Roos AJ, Mirick DK, Edlefsen KL, LaCroix AZ, Kopecky KJ, Madeleine MM, Magpantay L, Martínez-Maza O. Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma. Cancer Res 2012; 72:4733-43; PMID:22846913; http://dx.doi.org/10.1158/0008-5472.CAN-12-1639
10. Ho AW, Hatjiharissi E, Ciccarelli BT, Branagan AR, Hunter ZR, Leleu X, Tournilhac O, Xu L, O'Connor K, Manning RJ, et al. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood 2008; 112:4683-9; PMID:18216294; http://dx.doi.org/10.1182/blood-2007-04-084525
11. van Oers MH, Pals ST, Evers LM, van der Schoot CE, Koopman G, Bonfrer JM, Hintzen RQ, von dem Borne AE, van Lier RA. Expression and release of CD27 in human B-cell malignancies. Blood 1993; 82:3430-6; PMID:8241510
12. Duggleby RC, Shaw TN, Jarvis LB, Kaur G, Gaston JS. CD27 expression discriminates between regulatory and non-regulatory cells after expansion of human peripheral blood CD4+ CD25+ cells. Immunology 2007; 121:129-39; PMID:17425604; http://dx.doi.org/10.1111/j.1365-2567.2006.02550.x
13. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood 2007; 110:2537-44; PMID:17615291; http://dx.doi.org/10. 1182/blood-2007-03-082578
14. Jak M, Mous R, Remmerswaal EB, Spijker R, Jaspers A, Yagüe A, Eldering E, Van Lier RA, Van Oers MH. Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50:788-801; PMID:19452318; http://dx.doi.org/10.1080/10428190902803677
15. Claus C, Riether C, Schürch C, Matter MS, Hilmenyuk T, Ochsenbein AF. CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res 2012; 72:3664-76; PMID:22628427; http://dx.doi.org/10. 1158/0008-5472.CAN-11-2791
16. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
17. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278:3466-73; PMID:12427744; http://dx.doi.org/10.1074/jbc.M210665200
18. Wyzgol A, Müller N, Fick A, Munkel S, Grigoleit GU, Pfizenmaier K, Wajant H. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol 2009; 183:1851-61; PMID:19596991; http://dx.doi.org/10.4049/jimmunol.0802597
19. Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, Matsushima K, Ueda R, Hanai N, Shitara K. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004; 64:2127-33; PMID:15026353; http://dx.doi.org/10.1158/0008-5472.CAN-03-2068
20. Yano H, Ishida T, Imada K, Sakai T, Ishii T, Inagaki A, Iida S, Uchiyama T, Ueda R. Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF. Br J Haematol 2008; 140:586-9; PMID:18205860; http://dx.doi.org/10.1111/j.1365-2141.2007.06947.x
21. Kara IO, Sahin B, Gunesacar R. Expression of soluble CD27 and interleukins-8 and -10 in B-cell chronic lymphocytic leukemia: correlation with disease stage and prognosis. Adv Ther 2007; 24:29-40; PMID:17526459; http://dx.doi.org/10.1007/BF02849990
22. Lens SMA, Tesselaar K, van Oers MHJ, van Lier RAW. Control of lymphocyte function through CD27-CD70 interactions. Semin Immunol 1998; 10:491-9; PMID:9826582; http://dx.doi.org/10.1006/smim.1998.0154
23. Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS; MDX010-20 Investigators. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013; 119:1675-82; PMID:23400564; http://dx.doi.org/10.1002/cncr.27969
24. Polak ME, Newell L, Taraban VY, Pickard C, Healy E, Friedmann PS, Al-Shamkhani A, Ardern-Jones MR. CD70-CD27 interaction augments CD8+ T-cell activation by human epidermal Langerhans cells. J Invest Dermatol 2012; 132:1636-44; PMID:22377764; http://dx.doi.org/10.1038/jid.2012.26
25. Israel BF, Gulley M, Elmore S, Ferrini S, Feng WH, Kenney SC. Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas. Mol Cancer Ther 2005; 4:2037-44; PMID:16373719; http://dx.doi.org/10.1158/1535-7163.MCT- 05-0253
26. Kenney S. Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors. Trans Am Clin Climatol Assoc 2006; 117:55-73, discussion 73-4; PMID:18528464
27. McEarchern JA, Smith LM, McDonagh CF, Klussman K, Gordon KA, Morris-Tilden CA, Duniho S, Ryan M, Boursalian TE, Carter PJ, et al. Preclinical characterization of SGN-70, a humanized antibody directed against CD70. Clin Cancer Res 2008; 14:7763-72; PMID:19047103; http://dx.doi.org/10.1158/1078-0432. CCR-08-0493
28. Oflazoglu E, Stone IJ, Gordon K, Wood CG, Repasky EA, Grewal IS, Law CL, Gerber HP. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res 2008; 14:6171-80; PMID:18809969; http://dx.doi.org/10.1158/1078- 0432.CCR-08-0916
29. de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, de Bruïne AP, Arends JW, Hoogenboom HR. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 1999; 274:18218-30; PMID:10373423; http://dx.doi.org/10.1074/jbc.274.26.18218
30. Baca M, Presta LG, O'Connor SJ, Wells JA. Antibody humanization using monovalent phage display. J Biol Chem 1997; 272:10678-84; PMID:9099717; http://dx.doi.org/10.1074/jbc.272.16.10678